2014年5月16日 · Bemfola is a medicine that contains the active substance follitropin alfa. It is used to treat the following groups: women who are undergoing assisted reproductive techniques (fertility treatment) such as fertilisation. Bemfola is given to stimulate the ovaries to produce more than one egg at a time;

Bemfola is intended for subcutaneous use. The injection should be given at the same time each day. The first injection of Bemfola should be performed under direct medical supervision. Self-administration of Bemfola should only be performed by patients who are well motivated, adequately trained and have access to expert advice.

In adult women: anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate; stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer (GIF...

BEMFOLA is a trademark and brand of FINOX AG, Burgdorf 3401, SWITZERLAND. This trademark was filed to EUIPO on Tuesday, March 20, 2012. The BEMFOLA is under the trademark classification: Medical Instrument Products; Pharmaceutical Products; The BEMFOLA trademark covers Surgical apparatus and instruments.;Chemico-pharmaceutical preparations.

Bemfola is an approved biosimilar to the reference product Gonal-f®. Comparability in safety, efficacy and quality between Bemfola and Gonal-f® have been established. Bemfola can be used to bring about the development of follicles in women who are not ovulating and who have not responded to treatment with clomiphene citrate.

2018年7月10日 · Both BEMFOLA® and the reference product GONAL-f® are formulations of the naturally occurring hormone FSH, which plays a key role in human reproduction. BEMFOLA® was granted marketing authorisation in EU in May 2014 and is currently registered in 40 countries. The European MA for BEMFOLA® was supported by data from a

The drug BEMFOLA contains one active pharmaceutical ingredient (API): In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles. This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

Ces cookies sont nécessaires au fonctionnement du site internet et ne peuvent pas être désactivés dans nos systèmes. Ils ne sont généralement définis qu'en réponse à des actions que vous effectuez et qui équivalent à une demande de services, telles que la définition de vos préférences en matière de confidentialité, la connexion ou le remplissage de formulaires.

Bemfola is intended for subcutaneous use. The injection should be given at the same time each day. The first injection of Bemfola should be performed under direct medical supervision. Self-administration of Bemfola should only be performed by patients who are well motivated, adequately trained and have access to expert advice.

Official information about Bemfola from the EMA website: SPC for healthcare professionals and package leaflet for the public.